<DOC>
	<DOCNO>NCT02445404</DOCNO>
	<brief_summary>It recommend CHOP regimen primary T-cell lymphoma therapy currently use get satisfactory effect therapy ( progression-free survival 40 % ) , primarily consider clinical trial NCCN guideline.But CHOP regimen widely use physician accustom use . Fractionated ICED therapy therapy adjust Original ICE regimen.This capacity Ifosfamide divide three day . ( Fractionated ifosfamide ) .Original ICE therapy widely use salvage therapy patient relapse refractory lymphoma long time , recommend part primary therapy T-cell lymphoma.But Fractionated ICED add dexamethasone therapy order improve effectiveness primary therapy.The recurrent lymphoma 75 patient treatment Fractionated ICE self-stem cell transplantation , show 40 % progression-free survival.Thus treatment Fractionated ICED target previously untreated patient , combination high-dose dexamethasone expect able induce progression-free survival 60 % .</brief_summary>
	<brief_title>Study Compare Efficacy CHOP Versus Fractionated ICED Transplant-eligible Patients With Previously Untreated Peripheral T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>1 . Age 1965 year 2 . Informed consent 3 . Subject able adhere study visit schedule protocol requirement . 4 . Histologically proven Peripheral Tcell Lymphoma , No prior chemotherapy treatment Peripheral Tcell Lymphoma It include follow subtypes . PTCL , otherwise specify Angioimmunoblastic Tcell lymphoma Anaplastic large cell lymphoma , ALKnegative type Enteropathyassociated Tcell lymphoma Hepatosplenic Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma Primary cutaneous gammadelta Tcell lymphoma Primary cutaneous CD8+ aggressive epidermotropic lymphoma Other non classifiable Tcell Lymphoma 5 . Performance status ( ECOG ) 0,1 2 6 . A negative pregnancy test prior treatment must available premenopausal woman 7 . Female childbearing potential ( FCBP ) must : contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) IP ; 3 month follow last dose IP.Male subject must practice true abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption , 3 month follow IP discontinuation . 8. life expectancy≥90day ( 3months ) 1 . Other serious medical illness psychiatric disorder 2 . Any state confusion interpretation test result . 3 . Other type lymphoma ex ) Bcell lymphoma 4 . Other type Tcell lymphoma Adult TCell Leukemia/Lymphoma NK/Tcell Lymphoma , Nasal Type ALKPositive Anaplastic LargeCell Lymphoma Cutaneous Tcell lymphoma primary cutaneous CD30+ lympho proliferative disorder primary cutaneous Anaplastic T cell lymphoma 5 . Priviously treat PTCL ( Except short period randomization corticosteroid ( period 8 day ) 6 . Previous radiation therapy 7 . CNS involvement . 8 . If contraindication chemorherapy 9 . Subject known historical active infection HIV . 10 . BM function : ANC &lt; 1.5 × 109/L ; Platelet count &lt; 100,000/mm2 ( 100 × 109/L ) , SGOT/AST SGPT/ALT ≥ 3.0 x ULN , Bilirubin &gt; 2 x upper normal value 11. serum creatinine level &gt; 2.0 x ULN 12 . Any malignancy within past 3 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri 13 . MUGA scan &lt; 45 % 14 . Those administered doxorubicin exceed 200 mg / m2 15 . Subject active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 16 . Breastfeeding pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>